245 Summer Street,
Boston , MA, 02210
Boston , MA, 02210
Summary
The fund seeks capital appreciation by investing in companies in the United States.
The investment process is designed to highlight companies that are engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes.
The process also focuses on companies that benefit significantly from scientific and technological advances in biotechnology.
Additiona More
Link
Directors
Oct 13, 2023- OSCAR MUNOZ
- ROBERT A LAWRENCE
- THOMAS A KENNEDY
- BETTINA DOULTON
- VICKI L FULLER
- THOMAS P BOSTICK
- PATRICIA L KAMPLING
- DENNIS J DIRKS
- DONALD F DONAHUE
- MICHAEL E WILEY
- SUSAN TOMASKY
- DAVID M THOMAS
- VIJAY ADVANI
Chief Compliance Officer
- JASON POGORELEC
Fund Manager(s)
Price
- 52-Week High/Low
- $26.91 - $17.02
- Turnover
- 43%
- Expense Ratio
- 1.73%
Company Name |
Holding |
| ABBVIE INC | 18.21 % |
| AMGEN INC | 9.43 % |
| Fidelity Revere Street Trust | 9.12 % |
| REGENERON PHARMACEUTICALS INC | 7.01 % |
| VERTEX PHARMACEUTICALS INC | 4.72 % |
| ALNYLAM PHARMACEUTICALS INC | 4.53 % |
| ARGENX SE | 3.76 % |
| ASCENDIS PHARMA A/S | 3.5 % |
| VAXCYTE INC | 2.61 % |
| CYTOKINETICS INC | 2.6 % |
| More | 2.6 % |
Documents
Performance
YTD
3.1%
3 Year
-9.6%
5 Year
16.69%
Best
62.44%
2013
Worst
-40.63%
2002
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | 8.4% | -5% | -8.5% | -23.4% | -11.5% | 14% | 2.6% | 14.4% | -27.9% | 14.4% |
| Q2 | - | 3.9% | -14.2% | 27.6% | 30% | -2.1% | 9.3% | 4.1% | 1.6% | 7.5% |
| Q3 | - | -5.1% | 9% | -19.5% | -9.4% | -9.3% | 5.4% | 10.5% | 13.3% | -23.3% |
| Q4 | - | 19.5% | 6.7% | -2.6% | 14.7% | 13.1% | -15.7% | -6.4% | -8.6% | 10.9% |
| J | F | M | A | M | J | J | A | S | O | N | D | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 4.1% | 6.5% | 1.9% | -7.2% | - | - | - | - | - | - | - | - |
| 2023 | 1.1% | -3.6% | -2.4% | 3.2% | 0.3% | 0.4% | 2.2% | -3% | -4.2% | -5.7% | 4.1% | 19.4% |
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3% | 10% | -9% | -23% | 20% | 16% | -5% | 25% | -24% | 5% |
Alpha
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| FBTCX | 3% | 10% | -9% | -23% | 20% | 16% | -5% | 25% | -24% | 5% |
| S&P 500 | - | - | -21% | 27% | 16% | 29% | -6% | 19% | 10% | -1% |
| Alpha | 3% | 10% | 13% | -50% | 3% | -13% | 2% | 5% | -34% | 5% |